Lactose-Modified Hyaluronic Acid Molecule Attenuates In Vitro Chondrocyte Inflammation
Cells · 2025
DOI: 10.3390/cells14241977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Alice Cristina Donato und 4 weiteren Autor:innen. Beteiligte Einrichtung: Histology Unit, Department of Molecular Medicine (DMM), University of Padova, 35121 Padova, Italy. Hauptthemen laut MEDLINE: Chondrocytes, Hyaluronic Acid, Lactose, Inflammation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlycoCore Pharma s.r.l. (Como, Italy).
Abstract (Originalsprache)
Background
Osteoarthritis (OA) is a chronic degenerative whole joint disease characterized by cartilage breakdown and inflammation. Galectin-3 (Gal-3), a β-galactoside-binding lectin secreted into the extracellular space, binds to glycosylated components of the extracellular matrix (ECM), modulating cell–matrix interactions and inflammation. This study aims to evaluate the anti-inflammatory effects of Hylach®, a hyaluronic acid (HA) derivative conjugated with lactose-based residues that bind Gal-3, on in vitro inflamed primary human chondrocytes.
Methods
Chondrocyte viability, after both Hylach® and HA treatments at different concentrations was assessed using the MTT assay. Two-dimensional and 3D cell cultures exposed to the conditioned medium (CM) of activated U937 monocytes and subsequently treated with Hylach or HA, were analyzed for the expression of IL-1β, IL-6, TNF-α, and Gal-3 at different time points (4, 10, and 24 h).
Results
HA and Hylach® did not affect cell viability at any of the tested concentrations. Both molecules reduced the overexpression of Gal-3 and pro-inflammatory molecules in 2D inflamed cell cultures, at both gene and protein levels. Notably, IL-1β, IL-6 and Gal-3 showed a more pronounced inhibitory effect at 4 h, with Hylach demonstrating a stronger reduction compared to native HA. Moreover, in inflamed 3D chondrocyte cultures, Hylach® but not HA, significantly reduced IL-1β, TNF-α and Gal-3 gene expression.
Conclusions
Hylach® exerts an early and more potent anti-inflammatory effect in inflamed 2D and 3D chondrocyte cultures when compared to HA. These findings suggest that targeting Gal-3 through selective HA derivatives may represent a promising strategy for modulating both inflammation and matrix remodelling in OA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Histology Unit, Department of Molecular Medicine (DMM), University of Padova, 35121 Padova, Italy.
- Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139 Milan, Italy.
- Musculoskeletal Pathology and Oncology Laboratory, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padova, Via Giustiniani 3, 35128 Padova, Italy.
- Orthopedics and Orthopedic Oncology, Department of Surgery, Oncology and Gastroenterology (DiSCOG), University Hospital of Padova, Via Giustiniani 3, 35128 Padova, Italy.
- Department of Biomedical Sciences (DBS), University of Padova, 35121 Padova, Italy.
ORCID-Profile: Elisa Belluzzi, Valentina Masola, Pietro Ruggieri, Paola Brun
Förderung
- GlycoCore Pharma s.r.l. (Como, Italy)
Zitieren
APA
Donato, A. C., Belluzzi, E., Masola, V., Ruggieri, P., & Brun, P. (2025). Lactose-Modified Hyaluronic Acid Molecule Attenuates In Vitro Chondrocyte Inflammation. Cells. https://doi.org/10.3390/cells14241977
Vancouver
Donato AC, Belluzzi E, Masola V, Ruggieri P, Brun P. Lactose-Modified Hyaluronic Acid Molecule Attenuates In Vitro Chondrocyte Inflammation. Cells. 2025. doi:10.3390/cells14241977
BibTeX
@article{Donato2025,
author = {Donato, Alice Cristina and Belluzzi, Elisa and Masola, Valentina and Ruggieri, Pietro and Brun, Paola},
title = {Lactose-Modified Hyaluronic Acid Molecule Attenuates In Vitro Chondrocyte Inflammation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14241977}
}
EUVIMED